ELXUSD
ELX / United States dollar
crypto

Hey everyone, back for the weekly briefing.
I'm the dev behind [CatalystAlert.io](https://catalystalert.io). Each week I pull from our calendar and lay out what's ahead so you can do your own research. Not investment advice, just the calendar.
Quick heads-up before we start: we're actively cleaning up false positive PDUFAs in our database (LLM-extracted dates from SEC filings that turned out to reference historical CRLs or third-party drugs). If something below looks off, **please call it out**, we just shipped a stricter verification pipeline this week and real-user feedback is what catches the stuff automation misses.
# Last Week's Scorecard (Apr 5-13), What actually happened
A heavy decision week. Here's what we've tracked:
**Approved / Positive:**
* **CORT** (Corcept Therapeutics), **Lifyorli APPROVED** ahead of the April 9 PDUFA date. First-in-class approval for ovarian cancer. Stock jumped \~8.5% on the announcement. $2.7B company.
**Pending / Unresolved in our data:**
* **DNLI** (Denali Therapeutics), Tividenofusp alfa PDUFA was **April 5** for Hunter Syndrome (MPS II). Outcome still unknown in our feed as of publication, double-check the latest press release. $1.9B company.
* **FBIOP** (Fortress Biotech), PDUFA was **April 6**. No confirmed outcome in our data yet. $73M micro-cap.
* **ROIV** (Roivant Sciences), PDUFA was **April 9**. Check company release for the decision.
* **AQST** (Aquestive Therapeutics), AQST-109 epinephrine oral film PDUFA was **April 11**. Novel delivery mechanism, watch for the FDA announcement.
If you have confirmed decisions for any of the above, drop them in the comments, we'll update the database.
# This Week (Apr 14-20), The Phase 3 avalanche
**April 15 is the single densest readout day we've seen this year.** Multiple $100B+ companies reporting Phase 3 data on the same day. Here's the confirmed lineup from ClinicalTrials.gov primary completion dates:
**The big names (April 15):**
* **LLY** (Eli Lilly), **Retatrutide** Phase 3 in obesity. Triple agonist (GLP-1/GIP/glucagon) that showed up to 24% weight loss in Phase 2. Coming right after the Foundayo/orforglipron approval. $770B company.
* **LLY** (Eli Lilly), Baricitinib Phase 3 in systemic juvenile idiopathic arthritis. Label expansion for the JAK inhibitor. $770B company.
* **ABBV** (AbbVie), ABBV-951 Phase 3 in Parkinson's Disease + Tavapadon Phase 3 in Parkinson's. Two Parkinson's readouts same day. $300B company.
* **AKRO** (Akero Therapeutics), **Efruxifermin** Phase 3 in NASH/MASH. FGF21 analog in the NASH market, one of the leading candidates alongside Madrigal's resmetirom.
* **IONS** (Ionis Pharmaceuticals), Eplontersen Phase 3 in transthyretin cardiomyopathy (ATTR-CM). Antisense approach. $5.7B company.
* **MRNA** (Moderna), mRNA-1345 Phase 3 in RSV. Competing against GSK's Arexvy and Pfizer's Abrysvo. $42B company.
* **GILD** (Gilead Sciences), Three HIV Phase 3 readouts same day (B/F/TAF, ISL/LEN, PTM B/F/TAF). Long-acting formulations, next-gen ART. $60B company.
* **ABVX** (Abivax), ABX464 Phase 3 in ulcerative colitis. $10B company.
* **UCBJY** (UCB), Staccato alprazolam Phase 3 in stereotypical prolonged seizures. $61B company.
**April 16-17:**
* **SNY / SNYNF** (Sanofi), NVX-CoV2705 Phase 3 (April 16) + Low-Dose RSVt vaccine Phase 3 (April 17). $115B company.
# Late April (Apr 21-30), Obesity war heats up, big pharma stacks readouts
**April 21, Novo Nordisk's big day:**
* **NVO** (Novo Nordisk), **Cagrilintide** Phase 3 in obesity. Amylin analog. $254B company.
* **NVO**, **Semaglutide** Phase 3 in obesity (new indication data). $254B company.
* **NVO**, **Concizumab** Phase 3 in congenital bleeding disorder. Anti-TFPI antibody. $254B company.
Three Novo readouts same day, this is their response to Lilly's Retatrutide week.
**April 24, Novartis:**
* **NVSEF / NVS** (Novartis), **Ianalumab** Phase 3 in primary immune thrombocytopenia (ITP). Anti-BAFF receptor antibody, novel mechanism. $299B company.
**April 27, Pfizer double:**
* **PFE** (Pfizer), Daratumumab + Elranatamab Phase 3 readouts in multiple myeloma. $143B company.
**April 29-30, Large cap cluster:**
* **AZN** (AstraZeneca), Three Phase 3 readouts across urothelial cancer, muscle-invasive bladder cancer, and advanced hepatocellular carcinoma. $314B company.
* **NVS** (Novartis), **Remibrutinib** Phase 3 in relapsing multiple sclerosis. $275B company.
* **RHHBY** (Roche), Multiple Phase 3 readouts in lymphoma, breast cancer, rheumatoid arthritis. $328B company.
* **VRTX** (Vertex), ELX/TEZ/IVA + IVA Phase 3 readouts in cystic fibrosis. $122B company.
* **OTSKF** (Otsuka), Centanafadine Phase 3 in ADHD. $32B company.
# PDUFA dates, Looking ahead (Late April - May)
⚠️ **Heads up on this section**: our PDUFA extraction pipeline had known issues with SEC full-text hallucinations. We just pushed a verification overhaul this week that auto-withdraws unverifiable PDUFAs. The list below shows dates we currently track, **always cross-check against FDA.gov, company IR pages, and recent 8-K filings** before acting on any of them.
|Expected|Ticker|Company|Notes|
|:-|:-|:-|:-|
|Apr 23|MRK|Merck|Track via investor relations|
|Apr 28|INSM|Insmed|Verify drug + indication before relying|
|May 6|LNTH|Lantheus|Verify application status|
|May 9|LNTH|Lantheus|Verify|
|May 12|AGIO|Agios|Verify|
|May 19|HRMY|Harmony Biosciences|Verify supplemental indication|
|May 25|VNDA|Vanda|Verify|
If any of these are wrong or stale, **tell us**, we'll trace the source and either correct or withdraw the catalyst.
# Themes to watch this window
**The obesity war enters round 3**, Lilly's Foundayo (oral GLP-1) was approved April 1. Retatrutide Phase 3 data drops April 15. Novo counters April 21 with Cagrilintide + Semaglutide + a new obesity indication for sema. Three data points in three weeks that will reshape the obesity narrative.
**NASH heavyweight check**, AKRO's Efruxifermin Phase 3 readout (April 15) against the Madrigal/Rezdiffra benchmark. The FGF21 vs THR-β mechanism comparison in real patients.
**RSV vaccine market**, Moderna's mRNA-1345 Phase 3 on April 15 + Sanofi's low-dose RSVt vaccine on April 17. Two RSV programs reporting within 48 hours, meaningful for the GSK/Pfizer duopoly currently dominating this market.
**April 15 density**, 11+ Phase 3 readouts from companies worth a combined $1.3T+ on a single day. Volatility spike likely across biotech ETFs.
# Free educational content on CatalystAlert
Free learning hub at [**catalystalert.io/learn**](https://catalystalert.io/learn), no signup:
* **PDUFA Dates Explained**, What FDA action dates mean and why they shift (8 min)
* **Advisory Committee Meetings**, How AdCom votes actually impact approvals (10 min)
* **Clinical Trial Phases**, Phase 1/2/3 design, endpoints, success rates (12 min)
* **FDA Special Designations**, Orphan Drug, Breakthrough, Fast Track, Priority (9 min)
* **Biotech Catalyst Trading**, How to identify, track, and position around catalysts (15 min)
* **NDA vs BLA Applications**, Drug vs biologics applications explained (6 min)
**Disclaimer:** The data presented is for informational purposes only and does not constitute investment advice. We are not a source of truth, dates, drug names, trial phases, and any other data points may contain errors, be outdated, or be inaccurate. Catalyst dates can shift, trials get delayed or cancelled, and outcomes are inherently uncertain. Always verify against official sources (SEC filings, FDA.gov, ClinicalTrials.gov, company press releases) before making any decisions. Use at your own risk.
# We want your feedback, especially the critical kind
Real talk: biotech data is messy. Press releases lag, FDA action dates slip, SEC filings reference historical CRLs that our LLM extractors can mistake for active PDUFAs. We just shipped a major cleanup this week that withdrew 12 false-positive PDUFAs our older extractor had mis-tagged as "Confirmed", including a CYTK omecamtiv date flagged by a commenter on the last post (**thank you**, that feedback directly triggered the fix).
So if you spot:
* A wrong date
* A drug that doesn't match the indication
* A PDUFA that was actually a CRL or never got resubmitted
* A Phase 3 that was already read out or discontinued
* A ticker mapped to the wrong company
* **Anything that just doesn't smell right**
**Drop a comment or DM.** Every correction we receive gets traced back to the source, and if it's a systemic issue we fix the pipeline so the same class of error can't recur. We're working every day to make this more accurate and more current, your skepticism is the best QA we have.
All data pulled from [CatalystAlert.io](https://catalystalert.io), built to track exactly this kind of stuff. Feedback, feature requests, bug reports all welcome.

Hey everyone, back for the weekly briefing.
I'm the dev behind [CatalystAlert.io](https://catalystalert.io). Each week I pull from our calendar and lay out what's ahead so you can do your own research. Not investment advice, just the calendar.
Quick heads-up before we start: we're actively cleaning up false positive PDUFAs in our database (LLM-extracted dates from SEC filings that turned out to reference historical CRLs or third-party drugs). If something below looks off, **please call it out**, we just shipped a stricter verification pipeline this week and real-user feedback is what catches the stuff automation misses.
# Last Week's Scorecard (Apr 5-13), What actually happened
A heavy decision week. Here's what we've tracked:
**Approved / Positive:**
* **CORT** (Corcept Therapeutics), **Lifyorli APPROVED** ahead of the April 9 PDUFA date. First-in-class approval for ovarian cancer. Stock jumped \~8.5% on the announcement. $2.7B company.
**Pending / Unresolved in our data:**
* **DNLI** (Denali Therapeutics), Tividenofusp alfa PDUFA was **April 5** for Hunter Syndrome (MPS II). Outcome still unknown in our feed as of publication, double-check the latest press release. $1.9B company.
* **FBIOP** (Fortress Biotech), PDUFA was **April 6**. No confirmed outcome in our data yet. $73M micro-cap.
* **ROIV** (Roivant Sciences), PDUFA was **April 9**. Check company release for the decision.
* **AQST** (Aquestive Therapeutics), AQST-109 epinephrine oral film PDUFA was **April 11**. Novel delivery mechanism, watch for the FDA announcement.
If you have confirmed decisions for any of the above, drop them in the comments, we'll update the database.
# This Week (Apr 14-20), The Phase 3 avalanche
**April 15 is the single densest readout day we've seen this year.** Multiple $100B+ companies reporting Phase 3 data on the same day. Here's the confirmed lineup from ClinicalTrials.gov primary completion dates:
**The big names (April 15):**
* **LLY** (Eli Lilly), **Retatrutide** Phase 3 in obesity. Triple agonist (GLP-1/GIP/glucagon) that showed up to 24% weight loss in Phase 2. Coming right after the Foundayo/orforglipron approval. $770B company.
* **LLY** (Eli Lilly), Baricitinib Phase 3 in systemic juvenile idiopathic arthritis. Label expansion for the JAK inhibitor. $770B company.
* **ABBV** (AbbVie), ABBV-951 Phase 3 in Parkinson's Disease + Tavapadon Phase 3 in Parkinson's. Two Parkinson's readouts same day. $300B company.
* **AKRO** (Akero Therapeutics), **Efruxifermin** Phase 3 in NASH/MASH. FGF21 analog in the NASH market, one of the leading candidates alongside Madrigal's resmetirom.
* **IONS** (Ionis Pharmaceuticals), Eplontersen Phase 3 in transthyretin cardiomyopathy (ATTR-CM). Antisense approach. $5.7B company.
* **MRNA** (Moderna), mRNA-1345 Phase 3 in RSV. Competing against GSK's Arexvy and Pfizer's Abrysvo. $42B company.
* **GILD** (Gilead Sciences), Three HIV Phase 3 readouts same day (B/F/TAF, ISL/LEN, PTM B/F/TAF). Long-acting formulations, next-gen ART. $60B company.
* **ABVX** (Abivax), ABX464 Phase 3 in ulcerative colitis. $10B company.
* **UCBJY** (UCB), Staccato alprazolam Phase 3 in stereotypical prolonged seizures. $61B company.
**April 16-17:**
* **SNY / SNYNF** (Sanofi), NVX-CoV2705 Phase 3 (April 16) + Low-Dose RSVt vaccine Phase 3 (April 17). $115B company.
# Late April (Apr 21-30), Obesity war heats up, big pharma stacks readouts
**April 21, Novo Nordisk's big day:**
* **NVO** (Novo Nordisk), **Cagrilintide** Phase 3 in obesity. Amylin analog. $254B company.
* **NVO**, **Semaglutide** Phase 3 in obesity (new indication data). $254B company.
* **NVO**, **Concizumab** Phase 3 in congenital bleeding disorder. Anti-TFPI antibody. $254B company.
Three Novo readouts same day, this is their response to Lilly's Retatrutide week.
**April 24, Novartis:**
* **NVSEF / NVS** (Novartis), **Ianalumab** Phase 3 in primary immune thrombocytopenia (ITP). Anti-BAFF receptor antibody, novel mechanism. $299B company.
**April 27, Pfizer double:**
* **PFE** (Pfizer), Daratumumab + Elranatamab Phase 3 readouts in multiple myeloma. $143B company.
**April 29-30, Large cap cluster:**
* **AZN** (AstraZeneca), Three Phase 3 readouts across urothelial cancer, muscle-invasive bladder cancer, and advanced hepatocellular carcinoma. $314B company.
* **NVS** (Novartis), **Remibrutinib** Phase 3 in relapsing multiple sclerosis. $275B company.
* **RHHBY** (Roche), Multiple Phase 3 readouts in lymphoma, breast cancer, rheumatoid arthritis. $328B company.
* **VRTX** (Vertex), ELX/TEZ/IVA + IVA Phase 3 readouts in cystic fibrosis. $122B company.
* **OTSKF** (Otsuka), Centanafadine Phase 3 in ADHD. $32B company.
# PDUFA dates, Looking ahead (Late April - May)
⚠️ **Heads up on this section**: our PDUFA extraction pipeline had known issues with SEC full-text hallucinations. We just pushed a verification overhaul this week that auto-withdraws unverifiable PDUFAs. The list below shows dates we currently track, **always cross-check against FDA.gov, company IR pages, and recent 8-K filings** before acting on any of them.
|Expected|Ticker|Company|Notes|
|:-|:-|:-|:-|
|Apr 23|MRK|Merck|Track via investor relations|
|Apr 28|INSM|Insmed|Verify drug + indication before relying|
|May 6|LNTH|Lantheus|Verify application status|
|May 9|LNTH|Lantheus|Verify|
|May 12|AGIO|Agios|Verify|
|May 19|HRMY|Harmony Biosciences|Verify supplemental indication|
|May 25|VNDA|Vanda|Verify|
If any of these are wrong or stale, **tell us**, we'll trace the source and either correct or withdraw the catalyst.
# Themes to watch this window
**The obesity war enters round 3**, Lilly's Foundayo (oral GLP-1) was approved April 1. Retatrutide Phase 3 data drops April 15. Novo counters April 21 with Cagrilintide + Semaglutide + a new obesity indication for sema. Three data points in three weeks that will reshape the obesity narrative.
**NASH heavyweight check**, AKRO's Efruxifermin Phase 3 readout (April 15) against the Madrigal/Rezdiffra benchmark. The FGF21 vs THR-β mechanism comparison in real patients.
**RSV vaccine market**, Moderna's mRNA-1345 Phase 3 on April 15 + Sanofi's low-dose RSVt vaccine on April 17. Two RSV programs reporting within 48 hours, meaningful for the GSK/Pfizer duopoly currently dominating this market.
**April 15 density**, 11+ Phase 3 readouts from companies worth a combined $1.3T+ on a single day. Volatility spike likely across biotech ETFs.
# Free educational content on CatalystAlert
Free learning hub at [**catalystalert.io/learn**](https://catalystalert.io/learn), no signup:
* **PDUFA Dates Explained**, What FDA action dates mean and why they shift (8 min)
* **Advisory Committee Meetings**, How AdCom votes actually impact approvals (10 min)
* **Clinical Trial Phases**, Phase 1/2/3 design, endpoints, success rates (12 min)
* **FDA Special Designations**, Orphan Drug, Breakthrough, Fast Track, Priority (9 min)
* **Biotech Catalyst Trading**, How to identify, track, and position around catalysts (15 min)
* **NDA vs BLA Applications**, Drug vs biologics applications explained (6 min)
**Disclaimer:** The data presented is for informational purposes only and does not constitute investment advice. We are not a source of truth, dates, drug names, trial phases, and any other data points may contain errors, be outdated, or be inaccurate. Catalyst dates can shift, trials get delayed or cancelled, and outcomes are inherently uncertain. Always verify against official sources (SEC filings, FDA.gov, ClinicalTrials.gov, company press releases) before making any decisions. Use at your own risk.
# We want your feedback, especially the critical kind
Real talk: biotech data is messy. Press releases lag, FDA action dates slip, SEC filings reference historical CRLs that our LLM extractors can mistake for active PDUFAs. We just shipped a major cleanup this week that withdrew 12 false-positive PDUFAs our older extractor had mis-tagged as "Confirmed", including a CYTK omecamtiv date flagged by a commenter on the last post (**thank you**, that feedback directly triggered the fix).
So if you spot:
* A wrong date
* A drug that doesn't match the indication
* A PDUFA that was actually a CRL or never got resubmitted
* A Phase 3 that was already read out or discontinued
* A ticker mapped to the wrong company
* **Anything that just doesn't smell right**
**Drop a comment or DM.** Every correction we receive gets traced back to the source, and if it's a systemic issue we fix the pipeline so the same class of error can't recur. We're working every day to make this more accurate and more current, your skepticism is the best QA we have.
All data pulled from [CatalystAlert.io](https://catalystalert.io), built to track exactly this kind of stuff. Feedback, feature requests, bug reports all welcome.